FindTrial
Sign In

Observational study to investigate the effectiveness and safety of Sevikar HCT in patients with essential hypertension

A prospective long-term observational study to investigate the effectiveness and safety of Sevikar HCT tablet in patients with essential hypertension in Korea

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0002196
Enrollment
3750
Registered
2017-01-13
Start date
2016-05-03
Completion date
Unknown
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Kyung Hee University Hosipital at Gangdong
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria ? Patients starting Sevikar HCT(Hydrochlorothiazide) treatment at study entry as part of their routine clinical care. ? Patients or legal representative of the patients must provide written informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria ? Patients who already received Sevikar HCT(Hydrochlorothiazide) prior study entry prior to 3 months. ? Patients who are participating in other clinical study ? Patients who investigator judged them eligible.

Design outcomes

Primary

MeasureTime frame
Change in SBP(Systolic Blood Pressure)—

Secondary

MeasureTime frame
Change in SBP(Systolic Blood Pressure);Change in DBP(Diastolic Blood Pressure);Attainment of BP target;drop out rate;drop out rate due to adverse events;adverse events rate—

Countries

Korea, Republic of

Contacts

Public ContactYoon Jin CHO

Daiichi-Sankyo Korea

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 14, 2026